MÜNCHEN

Pharma CRO SocraGroup becomes part of fast growing CERTANIA group

Munich, September 2023 – SocraGroup, a Full Service Contract Research Organisation (CRO) for clinical studies, consisting of SocraTec R&D and SocraMetrics, joins CERTANIA, a fast-growing group in the field of Testing, Inspection and Certification as well as scientific, laboratory and compliance services. The group of two closely cooperating CROs takes advantage of CERTANIA’s unique, entrepreneurial ownership model: The proven SocraGroup leadership team will retain managerial independence, while obtaining access to the resources of a larger group. This will enable SocraGroup to keep delivering its signature customer service, while allowing for growth and service broadening. SocraGroup and CERTANIA both stand for outstanding scientific quality and a strong commitment to latest ESG standards, striving to run sustainable and inclusive businesses.   

SocraGroup offers clinical trial services for pharmaceutical drug development. The services range along the entire value chain starting with strategic clinical consultancy, study design development, project management, early phase trials in two specialized clinical pharmacology units allowing studies with healthy subjects and patients, monitoring of mono- and multi-centric trials to data management, statistical analysis and provision of study results. Joining CERTANIA paves the way to the next development stage of the cutting-edge expert CRO. As first steps an own eCRF has been released and a highly professional pharmacovigilance team has been integrated to broaden the service portfolio. The proven SocraGroup management team will stay on board and continue to stand for excellence in delivery and customer service. 

CERTANIA creates a growth ecosystem for mid-sized, knowledge-leading companies becoming partners under one group ownership umbrella. CERTANIA’s entrepreneurial model enables continued superior customer value delivery as it provides the suitable size to develop and offer solutions for all relevant aspects of complex research projects. CERTANIA partner companies act with a large degree of entrepreneurial freedom, thereby enabling quick decisions and personal, trust-based customer relationships. 

Dr. Barbara Schug, founder of SocraGroup, about the strategic move: „With the joint expertise and the collaboration with other CERTANIA partner companies, we will become an even more credible solution provider for our clients. Being part of CERTANIA enables us to further invest into our infrastructure, like the recent integration of the pharmacovigilance group. Our clients will benefit from the continuous expansion of our CRO services“. 

Karsten Xander, managing director of CERTANIA, welcomes SocraGroup and extends the invitation to join this unique group to other entrepreneurs and owners of companies in the field of scientific, laboratory and compliance services: “We provide an opportunity to put their company into a future-proof structure. It is our fundamental aim to build a group for the long run, where strong partner companies flourish, while retaining their identity”.

About SocraGroup:
SocraGroup, consisting of SocraTec R&D and SocraMetrics, has been dedicated to pharmaceutical science for drug development for 25 years. The services cover early phase human pharmacology trials including FIM and phase I/II in their own CPUs. Direct patient access in the intensive monitoring unit within a university hospital provides excellent opportunities for seamless early phase development including classical pharmacokinetics but also conventional bioavailability and bioequivalence trials. The service also covers later stages of clinical development of phase II to IV like feasibility analysis, site selection and patient recruitment to clinical monitoring and data management. The infrastructure is dedicated to national multi-centre trials. SocraGroup operates out of Oberursel and Erfurt and runs a network of partners enabling for international trials. The inclusion of pharmacovigilance service in combination with the strong strategic consulting competence and experience provides excellent conditions also for start-up companies. The management team consisting of Juliana Brudel, Barbara Schug and André Warnke together with a highly experienced team of specialists for all service fields is a guarantee for highest quality of clinical trials enjoying a high level of acceptance by international authorities worldwide.  
About CERTANIA: 
Under the umbrella of CERTANIA Holding GmbH, a new global market player is created in the field of Testing, Inspection & Certification as well as scientific, laboratory and compliance services. This group offers medium-sized partners a sustainable home for their life’s work. CERTANIA enables entrepreneurs and owners to further develop their companies with like-minded people, while continuing to preserve their entrepreneurial roots, corporate culture, brand and values.About GREENPEAK Partners:
GREENPEAK Partners is a company builder with proven track record and comprehensive expertise in the foundation, development, and expansion of industry leaders. While executing its Buy & Build strategies, GREENPEAK aims to develop industry leaders by virtue of strong partnerships, ESG values, and aligned sustainable interests. To date, the GREENPEAK Partners team has built over 10 platforms, with annual revenues exceeding €1 billion. 

Dr. Barbara Schug, SocraGroup
+49 6171 5857 111
barbara.schug@socratec-pharma.de
www.socratec-pharma.de
www.socrametrics.de


Karsten Xander, CERTANIA
+49 151 2774 5545
kxander@certania.de
www.certania.de


 

Weitere News